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http://dx.doi.org/10.1016/j.stemcr.2017.02.016SUMMARYThe isolation or in vitro derivation of many human cell types remains challenging and inefficient. Direct conversion of human plurip-
otent stem cells (hPSCs) by forced expression of transcription factors provides a potential alternative. However, deficient inducible gene
expression in hPSCs has compromised efficiencies of forward programming approaches. We have systematically optimized inducible
gene expression in hPSCs using a dual genomic safe harbor gene-targeting strategy. This approach provides a powerful platform for
the generation of human cell types by forward programming.We report robust and deterministic reprogramming of hPSCs into neurons
and functional skeletal myocytes. Finally, we present a forward programming strategy for rapid and highly efficient generation of human
oligodendrocytes.INTRODUCTION
Despitemajor efforts todevelop robustprotocols for scalable
generation of human cell types from easily accessible and
renewable sources, thedifferentiationofhumanpluripotent
stem cells (hPSCs) into specific cell types often remains
cumbersome, lengthy, and difficult to reproduce.Moreover,
the recapitulation of developmental stages in vitro yields
fetal cells that often do not reach full maturation (Cohen
andMelton, 2011).More recently, forced expression of line-
age-specific master regulators resulting in direct reprogram-
ming of somatic cell types has provided an efficient alterna-
tive todirecteddifferentiation (Huanget al., 2014; Ieda et al.,
2010; Zhou et al., 2008). In particular, the direct conversion
of hPSCs, termed forward programming (Moreau et al.,
2016), combines the advantages of hPSC differentiation
and direct cellular reprogramming, enabling scalable and
rapid generation of human cell types (Zhang et al., 2013).
Currently available forward programming protocols are
largely based on lentiviral transduction of hPSCs, which
results in variegated expression or complete silencing of
transgenes (Darabi et al., 2012; Smith et al., 2008). Addi-
tional purification steps are usually necessary for enriching
the desired cell type. Lentiviral approaches randomly insert
transgenes into the genome bearing the risk of unwanted
interference with the endogenous transcriptional program.
Therefore, refinements to the current forward program-
ming approaches are desirable.Stem C
This is an open access artiAs the result of a systematic effort to optimize gene
expression in hPSCs, we arrived at a robust hPSC forward
programming platform by targeting all components of
the Tet-ON system required for inducible expression
of transcription factors into genomic safe harbor sites
(GSHs) (Sadelain et al., 2012). The Tet-ON system consists
of two components: a constitutively expressed transcrip-
tional activator protein responsive to doxycycline (dox)
(reverse tetracycline transactivator [rtTA]), and an inducible
promoter regulated by rtTA (Tet-responsive element) that
drives expression of the transgene (Baron and Bujard,
2000). Previous GSH-targeting strategies of the Tet-ON
system relied on introducing both elements into the
AAVS1 GSH of hPSCs, either separately (Hockemeyer
et al., 2009), or together (using an all-in-one Tet-ON vector)
(Ordova´s et al., 2015; Qian et al., 2014). Compared with
these designs, we reasoned that targeting each of the two el-
ements of the Tet-ON system into a different GSH would
have several advantages: inducible overexpression based
on dual GSH targeting would not be affected by promoter
interferencebetween the two transgenes (BaronandBujard,
2000), while homozygous GSH targeting would maximize
the number of safely targeted transgene copies. Moreover,
the larger cargo capacity in each of the transgenes would
permit increasedflexibility for transgenedesign, thus allow-
ing the insertion of large reprogramming cassettes.
Here we show that an optimized approach based on dual
GSH targeting of Tet-ON-controlled transgenes results inell Reports j Vol. 8 j 803–812 j April 11, 2017 j ª 2017 The Authors. 803
cle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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homogeneous, controllable, and extremely high expres-
sion of inducible transgenes in hPSCs. Application of the
optimized overexpression platform enabled us to develop
rapid and deterministic forward programming protocols
for mature human cell types.RESULTS
Development of an Optimized Inducible Transgene
Overexpression Method by Dual GSH Targeting
To optimize inducible transgene overexpression from
GSHs, we generated human embryonic stem cells (hESCs)
with inducible EGFP (i-EGFP) expression. Initially, we
tested four different designs (Figure S1A). These comprised
two all-in-one targeting constructs in which both rtTA and
i-EGFP expression cassettes (third-generation Tet-ON sys-
tem) were inserted into the same allele of the AAVS1 GSH
locus. In these constructs, the rtTA expression was under
the control of either an EF1a or CAG promoter. The other
two transgene designs were based on spatial separation of
the activator and responder into two distinct GSHs (Fig-
ure S1A). For this purpose, we sequentially targeted the
rtTA cassette into the human ROSA26 GSH (Bertero et al.,
2016) and an i-EGFP transgene into the AAVS1 GSH (Fig-
ures 1A and S1A–S1E) (Hockemeyer et al., 2009). Robust
and homogeneous inducible transgene expression was
achieved only when the dual GSH approach and a CAG
promoter for rtTA expression was used (Figure S1A). Impor-
tantly, the dual GSH-targeting approach was highly effi-
cient (Table S1), and did not affect hESC self-renewal or
differentiation (Figures 1H–1K).
Using the CAG promoter-based dual GSH-targeting
approach, we selected clonal lines that carried either oneFigure 1. Development of an Optimized Inducible Gene Overexpr
(A) Workflow for targeting the hROSA26 and AAVS1 loci with the Tet-
D10A nickase mutant Cas9 endonuclease; ZFN, zinc-finger nucleas
element.
(B) Schematic of the four outcomes following generation of dual GSH
on the number of successfully targeted alleles of the hROSA26 and A
(C) Detection of the rtTA protein by western blot in heterozygous (HE
targeting results in increased rtTA protein expression. hESCs with rand
hESCs are shown as positive and negative reference. a-Tubulin, loadi
(D) Median fluorescent intensity (MFI) of EGFP expression in the va
analyzed by flow cytometry in non-induced conditions (CTR) or follow
included for comparison. Statistical analysis of dox-treated groups d
clones (each data point, n = 1–5, represents a clonal line; mean ±
****p < 0.0001).
(E) Flow cytometry of EGFP OPTi-OX hESCs after 5 days of dox treatm
(F and G) EGFP induction and rescue kinetics (F) and dox dose-respo
biological replicates; mean ± SEM; all values normalized to the maxim
(H–K) Immunocytochemistry (ICC) for lineage-specific markers in und
the germ layers.or two copies of each of the transgenes (Figure 1B), and
observed that homozygous targeting of both elements
allowed maximal inducible overexpression (Figures 1C,
1D, S1E, and S1F). Under these conditions, EGFP expres-
sion was induced homogeneously in all cells, consistent
across multiple clones, and more than 50-fold higher
compared with EGFP expression via the strong constitutive
CAG promoter (Figures 1D, 1E, S1E, and S1F). Maximal
EGFP levels were reached approximately 4 days after induc-
tion, and expression was quickly reversed upon dox with-
drawal (Figure 1F). Moreover, EGFP expression could be
titrated by adjusting the dose of dox (Figure 1G). I-EGFP
expression was highly efficient in hESCs (Figures 1E and
1H), and during germ layer differentiation (Figures 1I–1K
and S1G). There was no detectable background expression
of EGFP in the absence of dox (Figures 1D, 1E, and S1G).
Taken together, these results established that homozy-
gous dual GSH targeting of the Tet-ON system is a powerful
strategy for homogeneous and controllable expression of
inducible transgenes in hPSCs and their derivatives. We
will refer to this platform as ‘‘OPTi-OX’’ (optimized induc-
ible overexpression).
Human Induced Neurons
To test the applicability of the OPTi-OX platform for for-
ward programming of hPSCs intomature cell types, we first
chose to generate excitatory cortical neurons, as previous
studies demonstrated that these can be readily derived
by lentiviral overexpression of pro-neuronal transcription
factors in hPSCs (Zhang et al., 2013).
To this end, we generated NGN2 OPTi-OX hPSCs (Fig-
ure 2A; Table S1), and treated them with dox in chemically
defined neuronal culture medium (Zhang et al., 2013).
Induction of NGN2 expression (Figure S2A) resulted inession System
ON system in hPSCs for inducible EGFP expression (i-EGFP). Cas9n,
es; rtTA, reverse tetracycline transactivator; TRE, Tet-responsive
-targeted inducible EGFP hESCs: clonal lines were categorized based
AVS1 loci.
T) and homozygous (HOM) hROSA26-CAG-rtTA hESCs. Homozygous
om integration of a second-generation rtTA (M2-rtTA) and wild-type
ng control.
rious dual GSH-targeted i-EGFP hESCs described in (B). Cells were
ing 5 days of dox. AAVS1-CAG-EGFP and wild-type (WT) hESCs were
emonstrated that EGFP levels were highest in double-homozygous
SEM; one-way ANOVA with post hoc Dunnett’s test; **p < 0.01,
ent. Non-induced cells were included as negative control.
nse (G) in EGFP OPTi-OX hESCs detected by flow cytometry (n = 2
um fluorescence intensity after 5 days of dox).
ifferentiated EGFP OPTi-OX hESCs and following differentiation into
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Figure 2. Forward Programming of hPSCs into Neurons
(A) Experimental approach for conversion of NGN2 OPTi-OX hPSCs into i-Neurons.
(B) Time course of i-Neuron generation from hESCs by qPCR demonstrating the expression pattern of pluripotency factors (OCT4
and NANOG), pan-neuronal (MAP2 and SYP), forebrain (BRN2, FOXG1), and glutamatergic neuronal marker genes (VGlut2, GRIA4) (n = 3
biological replicates; mean ± SEM; relative to PBGD and normalized to pluripotency).
(C) Phase contrast images illustrating the morphological changes during i-Neuron generation (a corresponding time-lapse is shown in
Movie S1).
(D) ICC for the pan-neuronal marker proteins bIII-tubulin (TUBB3) and microtubule-associated protein 2 (MAP2) during the generation of
i-Neurons.
(E) Quantification of bIII-tubulin-positive neuronal cells by ICC after 1 week of induction. Undifferentiated cells were used as negative
control, and numbers are reported for i-Neuron generation in newly isolated NGN2 OPTi-OX hESCs and after 25 passages.
(F and G) ICC for neuronal markers in i-Neurons 14 days after induction.downregulation of pluripotency factors and initiation of
the neuronal transcriptional program (Figure 2B). Dox-
treated cells extended neuronal processes as early as
3 days post induction. After 1 week, all cells displayed a
neuronal morphology and expressed the pan-neuronal
markers bIII-tubulin and MAP2 (Figures 2C–2E and Movie
S1). At this stage, induced neurons (i-Neurons) showed
strong expression of forebrain markers BRN2 and FOXG1,
and of glutamatergic neuronal genes GRIA4, VGLUT1,
and VGLUT2 (Figures 2B and 2F), indicative of an
excitatory cortical neuronal identity of the forward-pro-
grammed cells, consistent with previous reports (Zhang
et al., 2013). Short pulses of dox treatment for 4 days or
longer sufficed for complete conversion, and converted
cells did not rely on continuous transgene expression (Fig-
ures S2B and S2C). Importantly, we did not observe any
reduction in the efficiency of generating i-Neurons over
extended culture periods of the inducible hESCs (>25 pas-
sages, Figure 2E). Finally, we confirmed the applicability
of the NGN2 OPTi-OX system in hiPSCs (Figure 2G).806 Stem Cell Reports j Vol. 8 j 803–812 j April 11, 2017Collectively, these results demonstrated that OPTi-OX en-
ables robust and rapid forward programming of hPSCs
into cortical neurons.
Human Induced Skeletal Myocytes
To further explore the potential of OPTi-OX for forward
programming of hPSCs, we focused on generating human
skeletal myocytes. Existing protocols for the directed differ-
entiation of skeletal myocytes from hPSCs are difficult,
time consuming, and result in low and variable yields
(Chal et al., 2015). On the other hand, myogenic transdif-
ferentiation has been achieved by overexpressing the
transcription factor MYOD1 in somatic cell types, but the
ability of hPSCs to undergo MYOD1-induced forward
programming is a matter of debate (Abujarour et al.,
2014; Albini et al., 2013; Tanaka et al., 2013).
We therefore generatedMYOD1OPTi-OX hPSCs (Figures
3A and 3B and Table S1). However, induction of MYOD1
expression following dox treatment resulted in cell death
within 3–5 days, regardless of the culture medium used
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(data not shown). These findings demonstrated that
MYOD1 overexpression alone was not sufficient to drive
myogenesis in hPSCs, in agreement with the postulated ex-
istence of epigenetic barriers preventing forcedmyogenesis
(Albini et al., 2013).
Cellular reprogramming strategies can be enhanced by
combining transcription factor overexpression with extra-
cellular signaling cues (Bar-Nur et al., 2014). We conducted
a systematic screen for pro-myogenic factors by modu-
lating key signaling cascades that are implicated in primi-
tive streak formation, somitogenesis, and myogenesis
(Figure S3A). We found that the addition of all-trans reti-
noic acid (RA) in conjunctionwithMYOD1 overexpression
was sufficient for rapid and deterministic conversion of
hPSCs into myogenin and myosin heavy chain double-
positive myocytes after 5 days of induction (Figures 3C
and S3A). The effect of RA was concentration dependent
(data not shown), and mediated at least in part through
the receptor isoforms RARa and RARb (Figures S3B
and S3C).
Following minor optimization of the culture condi-
tions (see the Supplemental Experimental Procedures), we
arrived at a protocol resulting in nearly pure induced skel-
etalmyocytes (i-Myocytes). Reprogrammed cells developed
typical spindle-like, elongated morphology, underwent
extensive cell fusion, and exhibited strong and homoge-
neous myogenic marker expression on mRNA and protein
levels (Figures 3D–3H, S3D, and S3E; Movie S2). Further-
more, the addition of nanomolar concentrations of acetyl-
choline (ACh) or the selective ACh-receptor agonist carba-
chol resulted in muscle fiber contraction, demonstrating
the functionality of the i-Myocytes (Movie S3). Similar
results were obtained with i-Myocytes generated from
MYOD1 OPTi-OX hiPSCs (Figure S3F). Importantly, induc-
tion efficiency did not decrease over extended culture pe-Figure 3. Forward Programming of hPSCs into Skeletal Myocytes
(A) Experimental approach for rapid single-step conversion of MYO
treatment with dox and RA.
(B) Representative ICC for MYOD1 before (CTR) and after induction w
expression, paralleled by downregulation of the pluripotency factors
(C) Effect of RA onmyocyte forward programming compared with other
the entire signaling molecule screen).
(D) qPCR of the temporal expression pattern of pluripotency factors (
(n = 3 biological replicates, mean ± SEM; relative to PBGD and norma
(E and F) ICC for skeletal myocyte markers in i-Myocytes.
(G and H) Quantification of MHC-positive cells by flow cytometry 10
control, and figures are reported for i-Myocyte generation in newl
50 passages (+P50) (n = 3 biological replicates; mean ± SEM).
(I) qPCR for total MYOD1, endogenous MYOD1, and MYOG 2 days po
replicates; mean ± SEM).
(J) ICC for myogenin andmyosin heavy chain following 5 days of induc
cell clusters appeared when the dox concentration was lowered to 0.1
myocyte cell populations.
808 Stem Cell Reports j Vol. 8 j 803–812 j April 11, 2017riods (>50 passages, Figure 3H), thus demonstrating the
robustness and reproducibility of this method. Finally, we
noted that the levels of theMYOD1 transgene following in-
duction positively correlated with conversion efficiency
(Figures 3I and 3J), which highlights the importance of a
robust gene-delivery method. In conclusion, these data
demonstrated that the OPTi-OX platform enables robust
and rapid forward programming of hPSCs into skeletal
myocytes.
Human Induced Oligodendrocytes
Encouraged by our results deriving neurons and myocytes,
we sought to utilize the same overexpression system to
develop a forward programming protocol for oligodendro-
cytes. Oligodendrocytes are of critical importance for CNS
function and their loss or dysfunction plays a key role in
many neurological diseases. Unlike neurons (Zhang et al.,
2013), protocols for efficient generation of human oligo-
dendrocytes from renewable sources remain an unmet
need: currently available hPSC differentiation protocols
are extremely long (up to 200 days) and yield heteroge-
neous cell populations (Douvaras et al., 2014; Stacpoole
et al., 2013; Wang et al., 2013).
We generated OPTi-OX hPSCs bearing inducible SOX10
either alone or in combination with OLIG2 in the form
of a polycistronic expression cassette (Figure 4A). Although
cells induced with SOX10 alone robustly expressed
the oligodendrocyte precursor (OPC) marker O4 after
10 days of induction, these cells failed to differentiate into
myelin-expressing cells and died (Figure 4A). In contrast,
the OLIG2-SOX10 overexpressing cells progressed from
an O4-positive progenitor stage into a mature CNP/MBP-
positive phenotype after 20 days of induction (Figure 4A).
Moreover, gene expression analysis confirmed that
OLIG2-SOX10OPTi-OXhPSCs induced in oligodendrocyteD1 OPTi-OX hPSCs into skeletal myocytes (i-Myocytes) following
ith dox. This demonstrates homogeneous induction of transgene
NANOG and OCT4.
wise identical control (CTR) induction conditions (see Figure S2B for
top panel) and myocyte marker genes during i-Myocyte generation
lized to pluripotency).
days after induction. Undifferentiated cells were used as negative
y isolated MYOD1 OPTi-OX hESCs, or in the same cells following
st induction with different dox concentrations (n = 3 biological
tion with different dox concentrations. Non-converted, proliferative
25 mg/mL. Further reduction of dox resulted in an increase in non-
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Figure 4. Forward Programming of hPSCs into Oligodendrocytes
(A) ICC for inducible transgenes after 1 day of induction (left column), the OPC marker O4 after 10 days (middle), and the oligodendrocyte
markers CNP and MBP after 20 days (right).
(B) Experimental approach for rapid conversion of OLIG2-SOX10 OPTi-OX hPSCs into the oligodendrocyte lineage cells (i-OPCs and i-OLs).
(C and D) Characterization of i-OPCs by ICC for OPC surface markers (A2B5, O4, PDGFRA).
(legend continued on next page)
Stem Cell Reports j Vol. 8 j 803–812 j April 11, 2017 809
medium (Douvaras et al., 2014) supplemented with the
mitogens PDGFaa and FGF2 first passed through an OPC-
like stage, during which they remained proliferative and
co-expressed typical OPCmarkers (Figures 4B–4F). Remark-
ably, following withdrawal of mitogens, i-OPCs differenti-
ated into mature oligodendrocytes, expressing the typical
myelin-associated proteins (Figures 4G–4M).DISCUSSION
OPTi-OX is the result of a systematic effort to optimize gene
expression in hPSCs. It relies on a dual GSH-targeting strat-
egy for the Tet-ON system, overcoming the limitations of
viral-mediated transgene delivery forward programming
protocols (Abujarour et al., 2014; Darabi et al., 2012; Zhang
et al., 2013) and allows stronger andmore controlled trans-
gene overexpression compared with previous targeting ap-
proaches (Gonza´lez et al., 2014; Hockemeyer et al., 2009;
Ordova´s et al., 2015). Table S2 compares the gene-delivery
methods that have been used for transcription factor
expression in different hPSC forward programming ap-
proaches. Moreover, site-specific insertion of the two com-
ponents of the inducible gene expression system mini-
mizes genomic off-target effects and together with the
chemically defined medium compositions enhances the
reproducibility of the protocols.
The functionality of our platform is exemplified through
the production of several cell types. First, we show that
NGN2 andMYOD1OPTi-OXhPSCs can be used as an inex-
haustible source for highly scalable, rapid, single-step, vi-
rus-free, chemically defined, fully reproducible, and deter-
ministic generation of i-Neurons and i-Myocytes.
Finally, we successfully applied the OPTi-OX platform to
develop a forward programming protocol for generating
human oligodendrocytes. Recent studies demonstrated
that forced expression of transcription factors allows direct
conversion of rodent fibroblasts (Najm et al., 2013; Yang
et al., 2013), and primary human fetal neural stem cells
(Wang et al., 2014) into OPCs, but the reprogramming of(E) Characterization of i-OPCs by qPCR compared with hPSCs (PLURI)
included i-Neurons as negative control (n = 3 biological replicates; me
Dunnett’s test; *p < 0.05; **p < 0.01, ***p < 0.001, ****p < 0.0001
(F) Immunostaining for BrdU (left panel) and quantification of BrdU-
and concomitant BrdU-pulses (n = 3 biological replicates; mean ± SE
(G) qPCR of the temporal expression pattern of genes encoding for the
i-OL generation. OLIG2-SOX10 OPTi-OX hPSCs were induced in oligoden
of induction, mitogens were withdrawn to enable terminal differentia
PBGD and normalized to pluripotency).
(H) Quantification of CNP and PLP expressing i-OLs derived from OLI
ferentiated cells were used as negative control, and figures are repo
passages (+P50).
(I–M) ICC providing an overview (I) and high-magnifications (J–M) o
810 Stem Cell Reports j Vol. 8 j 803–812 j April 11, 2017renewable human cell sources into oligodendrocytes has
not been reported. While i-OPCs undergo the expected
morphological changes, and express mature markers in
monocultures in vitro, further characterization of the cells
using co-culture models and transplantation into myelin-
deficient mutants is needed.
Human oligodendrocytes are of considerable interest for
several applications. The efficiency and speed of the pre-
sented forward programming system will enable high-
throughput drug screens and toxicology testing, in vitro
modeling of hereditary leukodystrophies, and the devel-
opment of cell-transplantation strategies (Goldman et al.,
2012).
Transcription factor combinations for direct cellular
reprogramming into many cell types of clinical interest
are now available, including cardiomyocytes (Ieda et al.,
2010), pancreatic b cells (Zhou et al., 2008), and hepato-
cytes (Huang et al., 2014). We anticipate that the OPTi-
OX platform will be applicable for the generation of
many other cell types. Overall, the presented method can
provide the basis for inexhaustible, high-throughput, ho-
mogeneous, and large-scale manufacturing of many hu-
man cell types.EXPERIMENTAL PROCEDURES
Gene Targeting
Targeting of the hROSA26 and AAVS1 locus was performed as
described recently (Bertero et al., 2016). Targeting of the hROSA26
locus was done by nucleofection. Neomycin-resistant colonies
were picked and screened by genotyping. Correctly hROSA26-
rtTA-targeted cloneswere subsequently targetedwith the inducible
transgene cassette in the AAVS1 locus by lipofection. Resulting
puromycin-resistant colonies were picked and re-analyzed by
genotyping.
Inducible Transgene Expression and Forward
Programming
Inducible overexpression was performed with dual GSH-targeted
OPTi-OXhPSCs. Expression of inducible transgenes was prompted. As transcription of CSPG4 (NG2) was also detected in hPSCs, we
an ± SEM; all values relative to PBGD; one-way ANOVA with post hoc
; ns, p > 0.05).
positive cells following three serial passages of i-OPCs every 4 days
M; P, passage).
myelin-associated proteins (CNP, MAG, MBP, MOG, and PLP) during
drocyte medium supplemented with PDGFaa and FGF2. After 1 week
tion (n = 3 biological replicates; mean ± SEM; all values relative to
G2-SOX10 OPTi-OX hPSCs after 20 days of induction by ICC. Undif-
rted for newly isolated OLIG2-SOX10 OPTi-OX hPSCs and after 50
f mature pre-myelinating oligodendrocytes.
by adding dox to the culture medium. For forward programming
into neurons, skeletal myocytes, and oligodendrocytes, standard
medium conditions for the derivation of the respective cell types
were used. Gene and protein expression analysis was performed
as described recently (Bertero et al., 2016). Please refer to the Sup-
plemental Experimental Procedures for details on culture condi-
tions and analysis techniques.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, three figures, two tables, and three movies and can
be found with this article online at http://dx.doi.org/10.1016/j.
stemcr.2017.02.016.
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Figure S1. Related to Figure 1: Generation of hPSCs with inducible EGFP expression 
(A) Schematic of the four different GSH (hROSA26 and AAVS1) targeting strategies: the two 
components (rtTA trans-activator cassette and inducible TRE-EGFP responder cassette) of the Tet-ON 
system were targeted either separately into the hROSA26 and AAVS1 locus, respectively, or together 
into the same allele of the AAVS1 locus by using an all-in-one donor vector design. For both 
configurations rtTA expression is controlled either by an EF1α- or CAG-promoter. The resulting cell 
lines were treated with dox for 5 days. Phase contrast and EGFP-images demonstrate homogeneous 
EGFP expression only in the dual GSH-targeting strategy in which rtTA expression is under control of 
the CAG promoter. Abbreviations: RO26: human ROSA26 (hROSA26) locus; AAVS1: AAVS1 locus; 
5’-HAR/3’-HAR: upstream/downstream homology arm. SA: splice acceptor; T2A: T2A peptide 
A
Supplemental Figure 1, (Pawlowski et al. 2016)
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Phase EGFP
 (ribosomal skipping signal); Neo: neomycin resistance gene (neomycin phosphotransferase II); Puro: 
puromycin resistance gene (puromycin N-acetyltransferase); pA: polyadenylation signal; EF1α: human 
elongation factor 1α promoter; CAG: CMV early enhancer, chicken β-actin and rabbit β-globin hybrid 
promoter; EGFP: enhanced green fluorescent protein; CAG: (B) Schematic of the genotyping strategy 
used to identify correctly targeted hROSA26 and AAVS1 targeted hPSC lines. GSH-prom: hROSA26 
and AAVS1 promotor, respectively; WT: wild-type; Transgene: entire exogenous sequence integrated 
following targeting. Locus PCR: PCR spanning the targeted locus with both primers binding 
exclusively to genomic DNA outside the genomic sequence corresponding to the homology arms. Note 
that due to its high GC-content the CAG promoter cannot be amplified by routine PCR. Therefore, 
correct insertion of the CAG-containing expression cassette results in loss of a PCR amplicon. The 
presence of the wild-type band indicates the presence of non-targeted alleles, and loss of the wild-type 
band indicates homozygous targeting. 5’-INT/3’-INT PCRs: PCRs spanning the 5’- and 3’-insertion 
site, respectively. Correctly sized PCR amplicons indicate correct integration. 3’-BB PCR: PCR 
spanning the homology arm/targeting vector backbone junction. The presence of a PCR product 
indicates non-specific off-target integration of the donor plasmid. (C-D) Genotyping results for 
selected hROSA26-CAG-rtTA targeted (C) and AAVS1-TRE-EGFP re-targeted hPSCs (D). 
Heterozygous (HET) and homozygous (HOM) lines for each allele are shown. 1kb+: 1kb plus DNA 
ladder; WT: wild-type hPSCs; PL: targeting plasmid; H2O: water control. Refer to Supplemental Table 
1 for a summary of all genotyping results and Supplemental Table 2 for the sequence of all genotyping 
primers. (E) Representative flow cytometry analysis of the various dual GSH-targeted inducible EGFP 
hPSCs described in figure 1B. Cells were analyzed in control conditions (no dox, CTR) or following 5 
days of dox treatment (DOX). An hESC line in which EGFP expression is under control of a CAG 
promoter in the AAVS1 locus (Bertero et al. 2016) is included as a positive control and for 
comparison. Note that the FITC (EGFP) acquisition settings were set to enable plotting of the highest 
levels of EGFP expression. Thus, the negative control (wild-type) is located directly adjacent to the left 
y-axis. (F) Percentage of EGFP positive cells in the various dual GSH-targeted inducible EGFP hESCs 
(each data point represents an individual clonal line; n=1-5) (G) Representative EGFP flow cytometry 
plots in EGFP OPTi-OX hPSCs that were differentiated into the three germ layers. EGFP was induced 
with dox for the duration of the differentiation protocol (3 to 6 days, refer to Supplemental Methods). 
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 Figure S2. Related to Figure 2: Characterization of induced neurons 
(A) Representative immunocytochemistry for NGN2 in NGN2 OPTi-OX hPSCs before (NO DOX) and 
24h after induction with dox (DOX). The staining demonstrates robust and homogeneous induction of 
transgene expression. (B) Representative immunocytochemistry for the pan-neuronal marker 
neurofilament (NF) 7 days after the start of induction with dox. NGN2 OPTi-OX hPSCs were treated 
with doxycycline for 0, 1, 2, 3, 4 or 7 days, respectively. A minimum of 4 days of dox treatment was 
sufficient to yield the same number of neurons compared to the addition of dox supplementation 
throughout the experiment. (C) Representative phase contrast images of the same cultures shown in 
panel B. 
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 Figure S3. Related to Figure 3: Screening for chemically-defined culture conditions for the 
induction of skeletal myocytes and characterization of skeletal myocytes 
(A) Screening for pro-myogenic factors: MYOD1 overexpression was initiated in DMEM basal media 
supplemented with different modulators of signaling cascades implicated in mesoderm patterning, 
somitogenesis and myogenesis. Shown is the immunocytochemistry for the myocyte markers 
myogenin (MYOG) and myosin heavy chains (MYH) 5 days post induction. This screen suggested that 
FGF2, forskolin (an adenylyl cyclase activator), and SB-431542 (an Activin/Nodal signaling inhibitor) 
have minor beneficial effects on cell survival and induction of myogenin and myosin heavy chain. 
However, the addition of all-trans retinoic acid (RA) led to the best outcome regarding survival, cell 
morphology and marker expression. This culture condition was chosen for the generation of induced 
myocytes (i-Myocytes) from MYOD1 OPTi-OX hPSCs. (B) RA was replaced with a range of 
selective, isoform-specific RA-Receptor agonists throughout the myocyte induction protocol (pan-
RAR/RXR agonist: 9-cis RA 1µM; pan-RAR agonist: TTNPB 1µM; RARα agonist: BMS753 1µM; 
RARβ agonist: CD2314 1µM; RARγ agonist: BMS961 1µM). Immunocytochemistry for myogenin 
and myosin heavy chain 5 days post induction demonstrated that the enhancing effect of RA during 
myocyte induction are mediated through the RA receptor isoforms RARα and RARβ, but not RARγ. 
(C) qPCR analysis of the six retinoid and rexinoid receptors during myocyte induction demonstrated 
expression of RARα, RARβ and all three RXR isoforms, but not of RARγ throughout the course of i-
Myocyte generation, consistent with the expression pattern of RA receptors during developmental 
myogenesis (n=3 biological replicates; mean ± SEM). (D) qPCR analysis of pluripotency factors and 
myosin heavy chain (MHC) isoforms during myocyte induction demonstrated rapid downregulation of 
the pluripotency factors NANOG and OCT4 (left panel), and strong upregulation of all major human 
skeletal myocyte-specific MHC isoforms (encoded by the MYH gene family) during i-Myocyte 
generation. The upregulated MHC-isoforms included the two isoforms that are expressed during 
embryonic and postnatal muscle development (embryonic isoform MYH3; neonatal isoform MYH8), 
and three isoforms that are expressed in adult human skeletal muscle [MYH7 in slow-twitching (type I) 
fibers; MYH2 in fast-twitching fatigue-resistant (type IIa) fibers, and MYH1 in fast-fatigable (type IIx) 
fibers]. In contrast, MYH4 which represents the constituting MHC-isoform in fast-twitching, fast-
fatigable myocyte fibers in cats is not expressed in significant amounts in humans (<1%) and is also 
not induced throughout the forward programming time course (n=3 biological replicates; mean ± 
SEM). (E) i-Myocytes express a broad range of typical marker proteins, including F-actin (visualized 
through AlexaFluor488-conjugated Phalloidin toxin), neural cell adhesion molecule (NCAM), desmin 
(DES), myosin heavy chains (MYH), titin (TTN), α-actinin (ACTN2) and troponin T (TNNT), but not 
the myoblast progenitor markers PAX3 and PAX7. All samples were co-stained with myogenin. (F) 
Human MYOD1 OPTi-OX hiPSCs underwent myogenic induction comparably to their hESC 
counterparts, as demonstrated by immunocytochemistry for myogenin and myosin heavy chain 10 days 
post induction. 
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Table S1. Summary of genotyping results 
 
Locus Cell- 
Line 
Trans- 
gene 
# clones  
picked 
 
(a) 
# clones 
no on-tar. 
Integrat. 
(b) 
# clones 
HET 
+ off-targ. 
(c) 
# clones 
HOM 
+off-targ. 
(c) 
# clones 
HET 
 
(d) 
# clones 
HOM 
 
(d) 
Efficiency 
no off-tar. 
[%] 
(e) 
Efficiency 
total 
[%] 
(f) 
ROSA26 H9 rtTA 23/27/60* 2/3/1* 7/13/36* 5/3/6* 8/8/14* 1/0/3* 39/30/28* 91/89/98* 
ROSA26 iPSC rtTA 48 8 11 2 25 2 56 83 
AAVS1 H9 EGFP 12/12/24* 2/1/2* 0/0/0* 4/5/11* 0/1/4* 6/5/7* 50/50/46* 83/92/92* 
AAVS1 H9 NGN2 6 0 0 0 0 6 100 100 
AAVS1 iPSC NGN2 3 0 0 2 1 0 33 100 
AAVS1 H9 MYOD1 12 2 0 3 0 7 58 75 
AAVS1 iPSC MYOD1 3 0 1 1 0 1 33 100 
 
Refer to Figure S1B for a schematic and additional explanations of the PCR genotyping strategy used. 
(a) Number of clones that were picked for expansion and genotyping following nucleofection (for 
hROSA26 targeting) and lipofection (for AAVS1 targeting), respectively. The total numbers of drug 
resistant colonies (from which the stated numbers of colonies were picked) were approximately 200 
colonies per 10cm dish following nucleofection, and 20 colonies per well of 6-well plate following 
lipofection. 
(b) Incorrect targeting: No evidence of targeting (lack of bands in 5’- and 3’-integration PCR and 
presence of WT band in locus PCR) or evidence of targeting, but incorrect size of 5’- or 3’-integration 
PCR. 
(c) Correct on-target integration with additional random integration of the plasmid (bands in 3’-
backbone PCR). 
(d) Correct on-target integration (HET, heterozygous; HOM, homozygous). 
(e) Percentage of clones with correct on-target integration (without additional off-target integration). 
(f) Percentage of clones with correct on-target integration (with or without additional off-target 
integration). 
* The three numbers are from three different targeting experiments in hESCs. 
 
 Table S2. Overview of gene delivery strategies in forward programming experiments 
 
Gene Delivery Off-
switch 
 
(a) 
Resistance to 
Silencing 
 
(b) 
Expression 
level 
 
(c) 
Genomic 
homogeneity 
/integrity of 
targeted cells (d) 
Independency of 
optimized viral 
transduction 
(e) 
Repro-
ducibility 
 
(f) 
Reference 
*acute Lenti 
PGK 0 + + 0 0 + Albini et al. 2013 
*acute Lenti 
EF1α 0 + + 0 0 + Moreau et al. 2016 
*acute Lenti 
i-TRE + + 0 0 0 + Pang et al. 2011 
*acute Lenti 
i-TRE (select) + ++ ++ 0 + ++ Zhang et al. 2013 
**clonal Lenti/Pig 
i-TRE + ++ + + ++ 0 
Abujarour et al. 2014 
Tanaka et al. 2013 
Single GSH 
i-TRE ++ ++ ++ +++ +++ +++ This study 
Dual GSH 
i-TRE +++ +++ +++ +++ +++ +++ This study 
 
*acute: hPSCs are transduced with lentiviral vectors (Lenti) - encoding either a constitutive or 
inducible reprogramming factor expression cassette - at the beginning of each individual 
reprogramming experiment. 
**clonal: hPSCs are transduced with lentiviral vectors (Lenti) or piggyback vectors (Pig) – encoding an 
inducible reprogramming factor cassette – clonally expanded, and each clonal line is subsequently 
analyzed for its transgene expression and forward programming capacity. 
 
(a) An optimal gene delivery system for forward programming contains an on-/off-switch to allow for 
controlled transcription factor expression during the reprogramming process and turning-off after a full 
cellular conversion has been achieved. This cannot be achieved by using constitutive promoters for 
transcription factor expression such as the PGK- or EF1α-promoter. Moreover, it has been 
demonstrated that significant leaky expression may occur following random genomic integration of the 
inducible (i) TRE-promoter or by placing the i-TRE in close vicinity to a strong constitutive promoter. 
(b) An optimal gene delivery system for forward programming renders the reprogramming factors 
immune to endogenous silencing mechanisms. Acute viral transduction of hPSCs invariably leads to 
transgene silencing in a large proportion of transfected cells. This proportion can be reduced by 
including an antibiotic resistance gene to allow for positive selection of successfully transduced cells. 
However, the expression levels of these genes required for antibiotic resistance are typically orders of 
magnitudes smaller than expression levels of reprogramming factors required for the initiation of a 
successful conversion process. Therefore, in this case, positive selection does not accurately predict 
successful conversion. 
(c) An optimal gene delivery system for forward programming enables very high transgene expression 
levels to facilitate a successful conversion process (see Fig. 3I-J). Transgene expression levels are a 
direct function of the strength of the promoter and the effects of silencing/variegation mechanisms, 
which occur in an integration site-dependent manner.  
(d) An optimal gene delivery system for forward programming ensures that all successfully 
reprogrammed cells are genetically identical and free of genomic alterations that potentially interfere 
with target cell function. 
(e) An optimal gene delivery system for forward programming does not rely on optimization of 
protocols for the production and titration of lentiviral vectors and the subsequent transduction of 
hPSCs, which represent a traditionally difficult to transduce cell type. 
(f) An optimal gene delivery system for forward programming allows full predictability and 
reproducibility of the resulting forward programming protocol among different labs and users. 
Naturally, this is impossible to achieve if the protocol relies on the selection of a clonally expanded line 
with a randomly integrated transgene. Moreover, it is also difficult to achieve when hPSC-transduction 
protocols with highly-concentrated lentiviral vectors are required. 
 
 
 Supplemental Movies 
 
 
Movie S1. Related to Figure 2. Time-lapse of neuron induction 
 
Movie S2. Related to Figure 3. Time-lapse of myocyte induction 
 
Movie S3. Related to Figure 3. Response of induced myocytes to ACh-Receptor stimulation 
 Supplemental Experimental Procedures 
 
hPSC maintenance culture and germ layer differentiation 
Feeder- and serum-free hESC (H9 line; WiCell) and hiPSC (Cheung et al. 2012) culture was performed 
as previously described (Vallier 2011). Briefly, cells were plated on gelatin/MEF media-coated culture 
dishes [MEF-media consists of Advanced DMEM/F12 (90%, Gibco), fetal bovine serum (10%, Gibco), 
L-Glutamine (1mM, Gibco), 2-Mercaptoethanol (0.1mM, Sigma-Aldrich) and Penicillin/Streptomycin 
(1%, Gibco)], and cultured in chemically defined media [CDM, consisting of IMDM (50%, Gibco), 
F12 (50%, Gibco), concentrated lipids (100x, Gibco), monothioglycerol (450µM, Sigma-Aldrich), 
insulin (7µg/ml, Roche), transferrin (15µg/ml, Roche), bovine serum albumin fraction V (5mg/ml, 
Europa Bioproducts), and Penicillin/Streptomycin (1%)] supplemented with Activin-A (10ng/ml) and 
FGF2 (12ng/ml; both from Marko Yvonen, Department of Biochemistry, University of Cambridge). 
Cells were passaged in small clumps using collagenase every 5-6 days. 
 
Differentiation of hPSCs into the germ layers was induced in adherent hESC cultures in accordance to 
previously published directed differentiation protocols. Briefly, definitive endoderm was derived by 
culturing hPSCs for 3 days in CDM-PVA (without insulin) supplemented with FGF2 (20ng/ml), 
Activin-A (100ng/ml), BMP4 (10ng/ml, Marko Hyvonen, Dept. of Biochemistry, University of 
Cambridge), and LY-294002 (10µM, Promega) (Touboul et al. 2010). For derivation of 
neuroectoderm, hPSCs were cultured for 6 days in CDM-BSA supplemented with SB-431542 (10µM, 
Tocris), LDN-193189 (0.1µM, Tocris) and RA (0.1µM, Sigma) (Douvaras et al. 2014). Lateral plate 
mesoderm was obtained by culturing hPSCs for 36h in CDM-PVA supplemented with FGF2 20ng/ml, 
BMP4 (10ng/ml; R&D), and LY294002 (10µM), and for 3.5 subsequent days in CDM-PVA 
supplemented with FGF2 (20ng/ml) and BMP4 (50ng/ml) (Cheung et al. 2012). 
 
Gene targeting constructs and molecular cloning 
We recently described the design and construction of the hROSA26 gRNA/Cas9n expression plasmids 
and of the hROSA26 targeting vector, and demonstrated that this targeting strategy allows for 
homogeneous, strong and stable expression of targeted transgenes in hPSCs and their differentiated 
progenies (Bertero et al. 2016). The pR26_CAG-rtTA targeting vector was constructed by cloning the 
coding sequence of a third generation rtTA (Zhou et al. 2006) (PCR-amplified from pLVX-Tet3G) into 
the BamHI/MluI sites of pR26_CAG-EGFP (Bertero et al. 2016) thus replacing the EGFP sequence. 
 
AAVS1 ZFN expression plasmids were a generous gift of Dr. Kosuke Yusa, Wellcome-Trust Sanger 
Institute (Bertero et al. 2016). The inducible EGFP AAVS1 targeting vector was constructed by Gibson 
Assembly (New England Biolabs) in which three inserts were ligated into the EcoRI/HindIII sites of 
the multiple cloning site of the pUC19 vector (Thermo Fisher Scientific): The first insert comprised the 
upstream AAVS1 homology arm, a splice acceptor, a T2A-site and the puromycin resistance cassette 
(all these elements were PCR-amplified from pTRE-EGFP; addgene 22074, deposited by Rudolf 
Jaenisch). The second insert contained the inducible TRE3G promoter (PCR-amplified from pLVX-
TRE3G). The third insert comprised the EGFP expression cassette and the AAVS1 downstream 
homology arm (PCR-amplified from pTRE-EGFP; addgene 22074, deposited by Rudolf Jaenisch). The 
resulting plasmid was termed pAAV_TRE-EGFP. The pAAV_TRE-NGN2 and pAAV_TRE-MYOD1 
targeting vectors were constructed by cloning the NGN2 and MYOD1 coding sequence, respectively 
(NGN2: PCR-amplified from pLVX-TRE-NGN2 (Ladewig et al. 2012), gift from Oliver Brüstle; 
MYOD1, OLIG2, SOX10: PCR-amplified from commercially available cDNA plasmids, Open 
Biosystems) into the SpeI/EcoRI sites of pAAV_TRE-EGFP, thus replacing the EGFP sequence. 
 
Gene targeting 
Targeting of the hROSA26 locus (Irion et al. 2007) was performed by nucleofection. Human PSCs 
were dissociated to single cells with TrypLE Select (Gibco), and 2x106 cells were nucleofected (100µl 
reaction volume; total of 12µg of DNA, which was equally divided between the two gRNA/Cas9n 
plasmids and the targeting vector) using the Lonza P3 Primary Cell 4D-Nucleofector X Kit and cycle 
CA-137 of the Lonza 4D-Nucleofector System. Nucleofected hPSCs were plated onto irradiated multi-
drug resistant (DR4) mouse embryonic fibroblasts and cultured in KSR media [consisting of Advanced 
DMEM/F12 (80%), knock-out serum replacer (20%, Gibco), L-Glutamine (1mM), 2-Mercaptoethanol 
(0.1mM) and Penicillin/Streptomycin (1%)] supplemented with FGF2 (4ng/ml). Y-27632 (5µM, 
Tocris) was added for 24h before and after nucleofection to promote cell survival. After 3-6 days, 
neomycin-resistant hPSCs were selected by adding G418 (50 µg/ml, Sigma-Aldrich) for 7-10 days. 
 Subsequently, individual clones were picked, expanded in feeder-free conditions and finally analyzed 
by genotyping. 
 
Targeting of the AAVS1 locus (Hockemeyer et al. 2009) was performed by lipofection. Human PSCs 
were seeded in feeder-free conditions in 6-well plates, and transfected 48h after passaging. 
Transfection was performed in Opti-MEM (Gibco) supplemented with Lipofectamine2000 (10 µl/well, 
Thermo Fisher Scientific) and a total of 4 µg of DNA (equally divided between the two AAVS1 ZFN 
plasmids and the targeting vector) for 24h. After 3-5 days, resistant hPSCs were selected by adding 
puromycin (1µg/ml, Sigma-Aldrich) for 5-8 days. Subsequently, individual clones were picked, 
expanded and analyzed by genotyping. 
 
Drug-resistant hPSC clones from targeting experiments were screened by genomic PCR to verify site-
specific transgene integration, to determine the number of targeted alleles, and to exclude off-target 
integrations. PCRs were performed with LongAmp Taq DNA Polymerase (New England Biolabs). The 
primer combinations used for the various targeting vectors are reported in supplemental experimental 
procedures. The results of all targeting experiments are summarized in Supplemental Table 1. 
Karyotype analysis was performed by standard G banding techniques (Medical Genetics Service, 
Cambridge University Hospitals). To prepare the targeted human PSCs for chromosome analysis, cells 
were incubated in fresh culture media supplemented with Y-27632 (5µM, Tocris) and KaryoMAX 
Colcemid (100ng/ml, Gibco) for 4h at +37°C. Subsequently, cells were harvested as single cells, 
washed, and pelleted. Nuclei swelling and spreading of the chromosomes was achieved by treatment 
with hypotonic 0.055 M KCl-solution for 5 minutes. Finally, cells were fixed and preserved in 
methanol and glacial acetic acid (ratio 3:1). 
 
Induction of neurons 
Pluripotent NGN2 OPTi-OX cells were dissociated into single cells with TrypLE and plated onto 
Matrigel (35 µg/cm2, Scientific Laboratory Supplies) coated dishes at a density of 75.000 cells per well 
of a 12-well plate. Forward programming was initiated 24 hours after the split. The induction was 
performed in DMEM/F12 (Gibco) supplemented with Glutamax (100x, Gibco), Non-Essential Amino 
Acids (100x, Gibco), 2-Mercaptoethanol (50µM), Penicillin/Streptomycin (1%), and dox (1µg/ml). 
After 2 days of induction, the medium was switched to Neurobasal-medium supplemented with 
Glutamax (100x), B27 (50x, Gibco), BDNF (10 ng/ml, Peprotech), NT3 (10 ng/ml, R&D Systems), 
Penicillin/Streptomycin (1%), and dox (1µg/ml). These culture conditions were based on previously 
described chemically-defined neuronal basal culture media (Zhang et al. 2013), and used for all 
experiments presented. Cells were cultured for 7-14 days before analysis. 
 
Induction of skeletal myocytes 
Pluripotent OPTi-MYOD1 cells were dissociated into single cells with TrypLE and plated onto 
gelatine/MEF-medium coated dishes at a density of 100.000 cells per well of a 12-well plate. Forward 
programming was initiated 24 hours after the split. Unless stated otherwise, the induction was 
performed in DMEM (Sigma-Aldrich) supplemented with L-Glutamine (2mM), 2-Mercaptoethanol 
(50µM), Penicillin/Streptomycin (1%), insulin (7µg/ml), all-trans retinoic acid (1µM, Sigma-Aldrich), 
and doxycycline (1µg/ml). After 5 days of induction, the medium was supplemented with CHIR99021 
(3µM, Tocris) and heat-inactivated horse serum (2%, Gibco) to enhance maturation of the induced 
myocytes as previously described (Abujarour et al. 2014). Unless stated otherwise, these culture 
conditions were used in all experiments described in this paper. Additional reagents were tested during 
protocol optimization (see Fig. S2): DMEM/F12 (Gibco), IMDM (Gibco), DMEM (Sigma), α-MEM 
(Sigma), BMP4 (10ng/ml, Marko Hyvonen, Dept. of Biochemistry, University of Cambridge), cAMP 
(1µM, Sigma), Forskolin (20ng/µl, Tocris), IWR-1 (1µM, Tocris), LY-294002 (10µM), Purmophamine 
(1µM, Tocris), PD-0325901 (1µM, Tocris), LDN-193189 (0.1µM, Tocris), SB-431542 (10µM, 
Tocris), 9-cis RA (1µM, Sigma) TTNPB (1µM, Tocris), BMS753 (1µM, Tocris), CD2314 (1µM, 
Tocris), BMS961 (1µM, Tocris). 
 
Induction of oligodendrocytes 
Pluripotent OLIG2-2A-SOX10 OPTi-OX hPSCs were grown in colonies on gelatine/MEF coated 
culture dishes. Before the start of induction, they were treated with SB and LDN overnight. The 
following day induction was initiated in CDM supplemented with dox (1µg/ml) and RA (0.1 µM). One 
day after induction, cells were split in CDM supplemented with RA (0.1 µM), PM (1µM), and Y-27632 
(5µM), PDGFaa (20ng/ml, Peprotech), FGF2 (5ng/ml) onto PDL/laminin coated culture dishes 
(100.000 cells per well of a 12 well-plate). The following day cells were switched to oligodendrocyte 
 media consisting of DMEM/F12, supplemented with Glutamax (100x), Non-Essential Aminoacids 
(100x), 2-Mercaptoethanol (1000x), Penicillin-Streptomycin (100x), N2 Supplement (100x), B27 
Supplement (50x), Insulin 7µg/ml (Marko Hyvonnen), T3 60ng/ml (Sigma), Biotin 100ng/ml (Sigma), 
and db-cAMP 1µM (Sigma). Oligodendrocyte medium was supplemented with dox (1µg/ml), PDGFaa 
(20 ng/ml), FGF2 (5 ng/ml), RA (0.1 µM) and PM (1 µM). Seven days post induction RA and PM was 
withdrawn. To keep induced cells in a proliferative state, cells were passaged every 4 days (75.000 
cells per well of a 24-well plate) in the continued presence of the mitogens PDGFaa and FGF2. For 
differentiation of proliferative oligodendrocyte precursors, PDGFaa and FGF2 were withdrawn. 
Human recombinant NT3 (5ng/µl, R&D Systems) was added to enhance cell survival. 
 
Quantitative real-time PCR (qPCR) 
RNA was extracted using the GenElute Mammalian Total RNA Miniprep Kit and the On-Column 
DNAse I Digestion Set (Sigma-Aldrich). cDNA synthesis was performed with the Maxima First Strand 
cDNA Synthesis Kit (Thermo Fisher Scientific). Applied Biosystems SYBR Green PCR Master Mix 
was used for qPCR. Samples were run on the Applied Biosystems 7500 fast PCR machine. All samples 
were analyzed in technical duplicates and normalized to the house-keeping gene Porphobilinogen 
Deaminase 1 (PBGD). Results were analyzed with the ΔΔCt method. See supplemental experimental 
procedures for a full list of primer sequences. 
 
Flow cytometry 
For analysis of EGFP expression cells were harvested with TrypLE Select (Gibco) for 5-10 minutes at 
37°C to obtain a single cell suspension. Following a wash with PBS, cells were resuspended in ice-cold 
PBS supplemented with DAPI (10µg/ml), and incubated for 5 minutes on ice. Cells were analyzed 
using a Cyan ADP flow-cytometer to determine the levels of EGFP expression of viable cells (DAPI 
negative). EGFP levels in non-induced (not dox-treated) iEGFP cells were indistinguishable from wild-
type cells and served as negative control. FITC (EGFP) acquisition settings were set to enable plotting 
of the highest levels of EGFP expression. Thus, the negative control (wild-type and/or uninduced 
iEGFP cells) is in some instances located directly adjacent to the left y-axis. For staining and analysis 
of myosin heavy chain expression, cells were harvested with TrypLE Select (as for EGFP expression 
analysis), washed once with PBS, and fixed and permeabilized with Cytofix/Cytoperm solution (BD 
Biosciences). Subsequently, cells were washed and blocked in Perm/Wash buffer (BD Biosciences) 
supplemented with 3% bovine serum albumin (BSA) at +4°C overnight. Staining with a PE-conjugated 
anti-MYH antibody (supplemental experimental procedures) was carried out in Perm/Wash buffer for 
1h at +4°C in the dark. After three washes with Perm/Wash buffer cells were analyzed with a Cyan 
ADP flow-cytometer to determine the levels of MHC expression. Induced myocytes stained with an 
IgG2b isotype-control antibody served as negative control for gating purposes. Stained non-induced 
iMYOD1 OPTi-OX hPSCs served as experimental negative control. Data analysis was performed with 
FlowJo (v10) and Graphpad Prism (v6). 
 
Western blot 
Whole-cell protein was extracted with CelLytic M (Sigma-Aldrich) supplemented with complete 
Protease Inhibitor (Roche), and subsequently quantified by using Protein Quantification Kit-Rapid 
(Sigma-Aldrich). Protein electrophoresis was performed with NuPAGE LDS Sample Buffer and 4-12% 
NuPAGE Bis-Tris Precast Gels (Invitrogen). Following protein transfer on PVDF, membranes were 
blocked with PBS supplemented with 0.05% Tween-20 (PBST) 4% milk for 1h at room temperature, 
and incubated with primary antibodies overnight in PBST 4% milk. Membranes were washed with 
PBST, incubated with HRP-conjugated secondary antibodies (Sigma-Aldrich) in PBST 4% milk, 
incubated with Pierce ECL2 Western Blotting Substrate (Thermo Fisher Scientific), and exposed to X-
Ray Super RX Films (Fujifilm). 
 
Immunocytochemistry 
Cells were fixed in 4% paraformaldehyde (diluted in PBS) for 20 minutes at room temperature and 
subsequently washed three times with PBS. The cells were then blocked with 10% donkey serum 
(Sigma-Aldrich) and permeabilized with 0.3% Triton X-100 (diluted in PBS) for 20 minutes at room 
temperature. Subsequently, cells were incubated with appropriately diluted primary antibodies 
(supplemental experimental procedures) in 2% donkey serum and 0.1% Triton X-100 (diluted in PBS) 
at 4°C overnight. Triton-X was omitted throughout all steps when staining the surface antigen 
PDGFRA, A2B5, and O4. After three washes with PBS, the cells were incubated for 1 hour at room 
temperature with corresponding donkey fluorophore-conjugated secondary antibodies (Alexa Fluor 
488, 555, 568, and/or 647) in PBS supplemented with 1% donkey serum. Nuclei were visualized with 
 4',6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific). EGFP expression and 
immunostainings were imaged using a Zeiss LSM 700 confocal microscope (Leica). The percentage of 
βIII-tubulin positive cells was calculated by determining βIII-tubulin expression in at least 50 randomly 
selected DAPI-positive cells in 3 visual fields of 3 biological replicates using an inverted Olympus 
IX71 fluorescence microscope. 
 
Statistical analysis 
Statistical analysis was performed with GraphPad Prism (v6). The number of replicates, the statistical 
test used, and the test results are described in the figure legends. Unless stated otherwise data is 
presented as mean ± SEM. 
 
List of primers for genotyping PCR 
 
Locus PCR type Primer binding site Primer sequence 
hROSA26 
Locus PCR 
Genome (5') GAGAAGAGGCTGTGCTTCGG 
Genome (3') ACAGTACAAGCCAGTAATGGAG 
5'-INT PCR 
Genome (5') GAGAAGAGGCTGTGCTTCGG 
Splice Acceptor AAGACCGCGAAGAGTTTGTCC 
3'-INT PCR 
rtTA GAAACTCGCTCAAAAGCTGGG 
Genome (3') ACAGTACAAGCCAGTAATGGAG 
3'-BB PCR 
rtTA GAAACTCGCTCAAAAGCTGGG 
Vector Backbone (3') TGACCATGATTACGCCAAGC 
AAVS1 
Locus PCR 
Genome (5') CTGTTTCCCCTTCCCAGGCAGGTCC 
Genome (3') TGCAGGGGAACGGGGCTCAGTCTGA 
5'-INT PCR 
Genome (5') CTGTTTCCCCTTCCCAGGCAGGTCC 
Puromycin TCGTCGCGGGTGGCGAGGCGCACCG 
3'-INT PCR 
Transgene transgene specific sequence 
Genome (3') TGCAGGGGAACGGGGCTCAGTCTGA 
3'-BB PCR 
Transgene transgene specific sequence 
Vector Backbone (3') ATGCTTCCGGCTCGTATGTT 
 
List of primers for quantitative PCR 
 
Gene Orientation Primer sequence 
CNP 
Fw TCCTCATCATGAACAGAGGCTT 
Rev AAACTGCAGCTCAGGCTTGT 
CSPG4 
(NG2) 
Fw GTCGAGGACACCTTCCGTTT 
Rev GTGGTCAGCAGAGAGGACAC 
DES 
Fw CCAACAAGAACAACGACGCC 
Rev ATCAGGGAATCGTTAGTGCCC 
DMD 
Fw TGGTGGGAAGAAGTAGAGGACT 
Rev TGCTGCTTCCCAAACTTAGA 
EGFP 
Fw CCCGACAACCACTACCTGAG 
Rev GTCCATGCCGAGAGTGATCC 
FOXG1 
Fw TGCCAAGTTTTACGACGGGA 
Rev GGGTTGGAAGAAGACCCCTG 
GRIA4 
Fw GGCCAGGGAATTGACATGGA 
Rev AACCAACCTTTCTAGGTCCTGTG 
HMBS 
(PBGD) 
Fw ATTACCCCGGGAGACTGAAC 
Rev GGCTGTTGCTTGGACTTCTC 
MAG 
Fw CAGAAGACGTCCCCAACTCA 
Rev CCTCGGGAGGCTGAAATCATAA 
MAP2 Fw AGACTGCAGCTCTGCCTTTAG 
 Rev AGGCTGTAAGTAAATCTTCCTCC 
MBP 
Fw TGGTGATGGAGATGTCAAGCAGGT 
Rev GCTGTGGTTTGGAAACGAGGTTGT 
MOG 
Fw AGAGATAGAGAATCTCCACCGGA 
Rev TGATCAAGGCAACCAAGGGTC 
MYH1 
Fw CACACTAGTTTCACAGCTCTCG 
Rev CAGGGCACTCTTGGCCTTTA 
MYH2 
Fw GGAAGCTCTGGTGTCTCAGTT 
Rev CAGGGCGTTCTTGGCTTTTAT 
MYH3 
Fw GCTGCATACCCAGAACACCA 
Rev CCCTGCTGGCATCTTCTACC 
MYH4 
Fw TCGCATTTGTCAGCCAAGGG 
Rev TGAAACCCAGGATGTCCACAG 
MYH7 
Fw GAGACTGTCGTGGGCTTGTA 
Rev GCCCTTCTCAATAGGCGCATC 
MYH8 
Fw TGAAGCAGATAGCAGCGCGA 
Rev CGTACGAAGTGAGGGTGTGT 
MYOD1 
(endo) 
Fw GCCGCTTTCCTTAACCACAA 
Rev CTGAATGCCCACCCACTGTC 
MYOD1 
Fw CGACGGCATGATGGACTACA 
Rev TAGTAGGCGCCTTCGTAGCA 
NANOG 
Fw AGCAGATGCAAGAACTCTCCAA 
Rev TGAGGCCTTCTGCGTCACAC 
NEUROG2 
(NGN2) 
Fw TGTTCGTCAAATCCGAGACCT 
Rev CGATCCGAGCAGCACTAACA 
NKX2.2 
Fw GCTTCCTGCGTCCATTTCCG 
Rev GAAAGAAACTGGGGATGGGGAG 
OLIG1 
Fw TGTCGCAGAGAGTTTTCGCT 
Rev ATGCAAGGCGGTTGGTTTTC 
OLIG2 
Fw ATCGCATCCAGATTTTCGG 
Rev CCCCAGGGGAAGATAGTCGT 
PAX6 
Fw CGAGATTTCAGAGCCCCATA 
Rev AAGACACCACCGAGCTGATT 
PDGFRA 
Fw AGGGATAGCTTCCTGAGCCA 
Rev AGCTCCGTGTGCTTTCATCA 
PLP 
Fw AACAGCTGAGTTCCAAATGACC 
Rev ACGGCAAAGTTGTAAGTGGC 
POU3F2 
(BRN2) 
Fw ACCCGCTTTATCGAAGGCAA 
Rev CCTCCATAACCTCCCCCAGA 
POU5F1 
(OCT4) 
Fw GTGGAGGAAGCTGACAACAA 
Rev ATTCTCCAGGTTGCCTCTCA 
RYR1 
Fw CAATCGCCAGAACGGAGAGA 
Rev GTCGTGTTCCCTGTCTGTGT 
SLC17A6 
(VGLUT2) 
Fw GTAGACTGGCAACCACCTCC 
Rev CCATTCCAAAGCTTCCGTAGAC 
SOX10 
Fw ACACCTTGGGACACGGTTTT 
Rev GTCCAACGCCCACCTCC 
SYP 
Fw ACCTCGGGACTCAACACCTCGG 
Rev GAACCACAGGTTGCCGACCCAG 
SYN1 
Fw CCCTGGGTGTTTGCCCAGAT 
Rev ACCACGGGGTACGTTGTACT 
TUBB3 
Fw CAACCAGATCGGGGCCAAGTT 
Rev CCGAGTCGCCCACGTAGTT 
  
 List of antibodies 
 
Antigen Species Isotype Clonality Company Cat. No. Dilution 
A2B5 mouse IgM monoclonal Millipore MAB312 1:300 
ACTN2 (α-actinin) mouse IgG1 monoclonal Sigma A7811  1:200 
BrdU mouse IgG1 monoclonal BD Bio 347580 1:100 
CNP mouse IgG1 monoclonal Abcam ab6319 1:500 
DES (desmin) rabbit IgG monoclonal Abcam ab32362 1:500 
EOMES rabbit IgG polyclonal Abcam ab23345 1:200 
MAG mouse IgG1 monoclonal Abcam ab89780 1:400 
MAP2 mouse IgG1 monoclonal Sigma M4403 1:200 
MBP rat IgG2a monoclonal Millipore MAB386 1:200 
MYOD1 rabbit IgG monoclonal Abcam ab133627 1:250 
MYOG (myogenin) mouse IgG1 monoclonal DSHB F5D 1:100 
MYOG (myogenin) rabbit IgG monoclonal Abcam ab124800 1:500 
MYH (myosin heavy chains) mouse IgG2b monoclonal DSHB MF20 1:100 
MYH-PE mouse IgG2b monoclonal BD Biosc. 564408 1:20 (Flow) 
NANOG goat IgG polyclonal R&D AF1997 1:200 
NCAM mouse IgG1 monoclonal DSHB 5.1H11 1:100 
NEFH (neurofilament) rabbit IgG polyclonal Abcam ab8135 1:1000 
NEUROG2 (NGN2) rabbit IgG Polyclonal Santa Cruz sc-50402 1:100 
NKX2.5 rabbit IgG polyclonal Santa Cruz sc14033 1:200 
O4 mouse IgM monoclonal R&D MAB1326 1:1000 
OCT4 mouse IgG2b monoclonal Santa Cruz sc5279 1:200 
PAX3 mouse IgG2a monoclonal DSHB Pax3 1:100 
PAX6 mouse IgG1 monoclonal DSHB PAX6 1:100 
PAX7 mouse IgG1 monoclonal DSHB PAX7 1:100 
PLP rabbit IgG monoclonal Abcam Ab183493 1:2000 
SLC17A7 (VGLUT1) goat IgG polyclonal Abcam ab104899 1:500 
TNNT2 (troponin T) mouse IgG2a monoclonal DSHB CT3 1:100 
TTN (titin) mouse IgM monoclonal DSHB 9D10 1:100 
 TetR (tet repressor) mouse IgG1 monoclonal Clontech 631131 1:1000 (WB) 
TUBA4A (α4-tubulin) mouse IgG1 monoclonal Sigma T6199 1:10000 (WB) 
TUBB3 (βIII-tubulin) mouse IgG1 monoclonal Millipore MAB1637 1:1000 
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